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 Metabolomic Evaluation of Neutrophilic Airway 
Infl ammation in Cystic Fibrosis 
 Charles R.  Esther  Jr ,  MD ,  PhD ;  Raymond D.  Coakley ,  MD ;  Ashley G.  Henderson ,  MD ;  Yi-Hui  Zhou ,  PhD ; 
 Fred A.  Wright ,  PhD ; and  Richard C.  Boucher ,  MD 
 BACKGROUND:  Metabolomic evaluation of cystic fi brosis (CF) airway secretions could identify 
metabolites and metabolic pathways involved in neutrophilic airway infl ammation that could 
serve as biomarkers and therapeutic targets. 
 METHODS:  Mass spectrometry (MS)-based metabolomics was performed on a discovery set of 
BAL fl uid samples from 25 children with CF, and targeted MS methods were used to identify 
and quantify metabolites related to neutrophilic infl ammation. A biomarker panel of these 
metabolites was then compared with neutrophil counts and clinical markers in independent 
validation sets of lavage from children with CF and adults with COPD compared with control 
subjects. 
 RESULTS:  Of the 7,791 individual peaks detected by positive-mode MS metabolomics dis-
covery profi ling, 338 were associated with neutrophilic infl ammation. Targeted MS deter-
mined that many of these peaks were generated by metabolites from pathways related to the 
metabolism of purines, polyamines, proteins, and nicotinamide. Analysis of the independent 
validation sets verifi ed that, in subjects with CF or COPD, several metabolites, particularly 
those from purine metabolism and protein catabolism pathways, were strongly correlated with 
neutrophil counts and were related to clinical markers, including airway infection and lung 
function. 
 CONCLUSIONS:  MS metabolomics identifi ed multiple metabolic pathways associated with 
neutrophilic airway infl ammation. Th ese fi ndings provide insight into disease pathophysi-
ology and can serve as the basis for developing disease biomarkers and therapeutic interven-
tions for airways diseases.  CHEST 2015; 148(2): 507 - 515 
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 Chronic neutrophilic airway infl ammation is a hallmark 
of cystic fi brosis (CF) and contributes signifi cantly to 
morbidity and mortality. 1 Th is infl ammation can alter 
cellular metabolism, including extracellular metabolic 
pathways active within the airway lumen that generate 
biologically active molecules capable of initiating and 
modulating infl ammatory responses. 2-4 Metabolomics 
studies, which seek to characterize the full range of 
metabolites within biologic samples, suggest that CF is 
associated with signifi cant changes in the pattern and 
concentrations of metabolites in airway secretions, 
including elevated concentrations of amino acids and 
lactate in BAL fl uid (BALF) 5 and lipid mediators in spu-
tum. 6 Other studies have demonstrated that a metabo-
lomic signal of CF airways disease can be detected 
noninvasively in exhaled breath condensate (EBC), 7,8 
although the specifi c metabolites responsible for the 
signal were not identifi ed. Although these studies can 
provide new insights into pathophysiologic mechanisms 
and can identify new therapeutic targets and biomarkers 
of disease progression, 9,10 studies to date are limited by 
a lack of independent validation to verify results. 11 
 We hypothesized that a comprehensive metabolomic 
analysis of CF airways samples, obtained from subjects 
with various levels of infl ammation, may provide insight 
into the pathways associated with infl ammation and 
may identify new biomarkers and therapeutic targets. 
To this end, discovery mass spectrometry (MS) metabo-
lomics was performed in BALF from 25 children with 
CF, and a biomarker panel of relevant metabolites was 
developed. Th e relationships between these metabolites 
and infl ammation, infection, and lung function were 
then tested in independent validation sets of BALF 
from children with CF, as well as from adults with 
COPD and relevant control subjects. 
 Materials and Methods 
 Subjects and Samples 
 BALF from children with CF was collected during clinically indi-
cated bronchoscopy via standardized protocols 4 and was centrifuged 
at 11,000  3  g for 5 min, and the supernatant was stored at  2 80°C. 
Fifty pediatric subjects were included: 25 for discovery and 25 for 
validation ( Table 1 ). BALF from 10 subjects with COPD, 10 healthy 
smokers, and 10 healthy nonsmokers was obtained using a single 
lavage of 50 mL normal saline into the right middle lobe. Samples 
were placed on ice shortly after collection, centrifuged at 11,000  3  g 
for 5 min at 4°C to remove cellular material, and then frozen at 
 2 80°C until analysis. Both studies were approved by the University 
of North Carolina institutional review board (IRB Nos. 11-0828 and 
05-2876). Clinical data were abstracted from medical and research 
records. 
 Metabolomic profiling was performed by the David H. Murdock 
Research Institute. 12 Briefl y, 500- m L aliquots BALF were lyophilized 
and reconstituted in 100  m L 0.1% formic acid/50% acetonitrile, fil-
tered through 0.2- m m polytetrafluoroethylene , and analyzed on a 
UPLC-QtofMS system (ACQUITY UPLC-SYNAPT HDMS, Waters 
Corporation) operated in electrospray ionization positive mode. Chro-
matography used an ACQUITY UPLC BEH C18 1.7- m M VanGuard 
precolumn (2.1  3 5 mm) and an ACQUITY UPLC BEH C18 1.7- m M 
analytical column (2.1  3 100 mm) with gradients from 1% to 100% 
acetonitrile in 0.1% formic acid over 13 min. Data fi les were processed 
using MarkerLynx XS (Waters Corp), with peak detection and sig-
nal alignment as described. 12 Analysis occurred in two batches of 
10 and 15 samples, both of which included a range of neutrophilic 
infl ammation. 
 Targeted MS was performed using a Quantum-Ultra triple quadrupole 
mass spectrometer (Th ermo Finnigan LLC) in the multiple reaction 
monitoring mode. Chromatographic conditions similar to those of the 
metabolomics (UPLC BEH C18 column, acetonitrile/formic acid gradi-
ents) and previous work (UPLC T3 HSS C18 column, methanol/formic 
acid gradients 13 ) were explored, with the T3 column judged superior and 
used for validation. Validation BALF samples were spiked with isotopi-
cally labeled internal standard 14 and were fi ltered through a 10-kDa-size 
selection fi lter (EMD Millipore). Biomarker signals were defi ned as 
ratios to the internal standard with the closest column run time. 
 Statistical Analysis 
 Discovery metabolomic data were analyzed using robust principal 
component analysis (Y. H. Z. and J. S. Marron, PhD, unpublished data, 
2014). Relationships to infl ammation were tested using analysis within 
each of the two batches, with evidence summarized using Fisher com-
bined  P value. Th e false-discovery rate  q value was used to correct for 
multiple comparisons. For validation, data not normally distributed (by 
D’Agostino and Pearson omnibus normality test) were log transformed 
and analyzed using parametric methods, including Student  t tests, analysis 
of variance, and linear regression. Spearman correlations were used 
for relationships between percent neutrophils to metabolite to urea 
ratios. Categorical comparisons for demographic balance in discovery 
vs validation samples were made using the Fisher exact test. Statistical 
analyses were performed using GraphPad Prism v 5.0 (GraphPad Soft -
ware, Inc) and SAFExpress soft ware (Safexpress Pvt Ltd). 15  
 Results 
 Subjects and Samples 
 Two sets of BALF were obtained from children with 
CF: a discovery set of 25 samples and a validation set 
of 25 samples. Th e sets did not diff er in terms of age, 
sex, or range of infl ammation ( Table 1 ), and there was 
no overlap in subjects. Bacterial or fungal pathogens 
were recovered in 20 discovery set and 21 validation 
set samples, with  Staphylococcus ,  Pseudomonas , and 
 Haemophilus species the most common. A second vali-
dation set was obtained from adults with COPD, 
healthy nonsmokers, and healthy smokers (n  5 10 per 
group) ( Table 2) . Neutrophil counts and percent neutro-
phils in BALF were higher in those with COPD than 
in healthy control subjects, but were lower than in 
patients with CF. All subjects were fasting at the time 
of the procedure. 
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 TABLE 1  ]  Demographics of Subjects With CF 
Characteristic Discovery Set Validation Set  P Value for Diff erence
No . 25 25 ...
Age, y 9.6   5.8 (1-21.3) 10.4   3.9 (5-17.7) .592
Male, % 48 52 .786
Cell count,  3 10 6 cells/mL 3.7   3.6 (0.2-14.0) 4.0   4.8 (1.8-18.0) .868
PMNs, % 61.0   23.7 (4-91.5) 64.2   22.8 (5-89) .630
PMN count,  3 10 6 cells/mL 2.9   3.2 ( , 0.1-12) 3.1   3.9 ( , 0.1-14.8) .442
With pathogens, % 80 84 1.000
 Data are presented as mean   SD . CF  5 cystic fi brosis; PMN  5 polymorphonuclear leukocyte . 
 TABLE 2  ]  Demographics of Subjects With COPD 
Characteristic Healthy Nonsmokers Healthy Smokers Subjects With COPD  P Value
No. 10 10 10 ...
Age, y 27.6   7.6 30.5   10.0 53.3   9.7  , .01
Male, % 75 67 58 NS
Current smoker, a % 0 100 50 ND
FEV 1 , % predicted 97.3   10.1 97   11.2 55.7   21.7  , .01
Cell count,  3 10 6 cells/mL 2.2   1.2 2.5   1.1 4.3   6.7 .42
PMNs, % 4.1   2.1 6.6   5.4 42.5   33.7  , .01
PMN count,  3 10 6 cells/mL 0.09   0.03 0.14   0.09 0.66   0.64  , .01
 Data are presented as mean   SD . ND  5 not determined; NS  5 not signifi cant . See  Table 1 legend for expansion of other abbreviations. 
 a All subjects with COPD had a history of smoking. 
 MS Metabolomics on Discovery Samples 
 Positive-mode MS metabolomics 16 revealed 7,791 indi-
vidual peaks, with each peak defi ned as a specifi c mass-
to-charge ( m / z ) ratio and column run time. Total MS 
signal correlated positively with neutrophil counts 
( r  5 0.71,  P  , .001) ( Fig 1A ) . Principal component 
analysis revealed a clustering of low-infl ammation sam-
ples ( Fig 1B ), with a greater dispersion among the high-
infl ammation samples. 
 Potential biomarkers of neutrophilic infl ammation were 
identifi ed by both group (samples divided into groups 
along median neutrophil count) and correlation analyses 
(linear regression to neutrophil counts). In group 
analysis, 267 peaks distinguished higher infl ammation 
(neutrophil counts   2.0 million cells/mL [n  5 13]) 
from lower infl ammation (neutrophil counts   1.5 mil-
lion cells/mL [n  5 12]) groups (false discovery rate 
 q  , 0.05) ( e-Table 1 ). For correlation analysis, 140 peaks 
correlated with neutrophil counts (false discovery rate 
 q  , 0.15). Sixty-nine peaks overlapped. Th is resulted in 
a total of 338 unique peaks identifi ed as potential bio-
markers. Several  m / z ratios were present in multiple 
peaks, and 317 unique  m / z ratios were represented. 
 Identifi cation of Potential Biomarkers 
 Selected ion monitoring was utilized to determine 
which  m / z ratios associated with putative biomarkers 
generated peaks that were larger in higher- vs lower-
infl ammation samples. Full scans of each peak were then 
utilized to determine the fragmentation pattern of the 
metabolite generating that peak. Metabolite identifi ca-
tion was made by comparison with published literature 17 
and online resources such as the Human Metabolite 
Database (www.hmdb.ca) and was confi rmed by com-
parison with appropriate standards. Th ese analyses sug-
gested that the putative biomarkers included the 
following metabolic pathways (e-Appendix 1). 
 Purine Metabolism:  Th e putative biomarker peak at 
 m / z 137.1 was identifi ed as hypoxanthine, a metabolic 
product of adenyl purines identifi ed previously as neu-
trophilic infl ammation biomarkers. 4 In addition, several 
biomarker peaks observed at  m / z 136.1 were consistent 
with adenine, the primary fragmentation ion of adenyl 
purines, 13 which may have been generated by in-source 
fragmentation of adenyl purines. 
 Polyamine Metabolism:  Potential biomarker peaks 
at  m / z 188.1, 146.1, and 89.1 were identified as 
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N-acetyl-spermidine, spermidine, and putrescine, all part 
of the polyamine synthesis pathway. Furthermore, free 
adenine can be generated during polyamine synthesis, 18 
which may account for one of the previously noted 
peaks at  m / z 136.1. 
 Protein Catabolism:  Several biomarker peaks had  m / z 
ratios consistent with that of amino acids; these included 
proline ( m / z 116.1), valine ( m / z 118.1), threonine 
( m / z 120.1), leucine/isoleucine ( m / z 132.1), glutamine 
( m / z 147.1), and phenylalanine ( m / z 166.1). Analysis of 
the internal library suggested that  m / z 188.1 represented 
an in-source fragmentation product of tryptophan. Free 
amino acids can be generated by protease activity in CF 
airways, 19 suggesting that other peptide fragments may 
also be represented. Th e biomarker peak at  m / z 229.1 
fragmented into major daughter ions at  m / z 116.1 and 
132.1, suggestive of a leucine-proline dipeptide, and 
the peak coeluted with a leucine-proline standard. 
Other putative biomarkers consistent with dipep-
tides included those at  m / z 173.1 (glycine-proline), 
260.1 (lysine-leucine), 267.1, (threonine-phenylalanine), 
and 279.1 (leucine-phenylalanine). 
 Nicotinamide Metabolism:  Th e putative biomarker at 
 m / z 123.1 was identifi ed as nicotinamide based on an 
internal library, and its fragmentation pattern (major 
daughter ion at  m / z 95.1) and chromotographic elution 
time were identical to those of authentic nicotinamide. 
 Validation of Potential Biomarkers 
 Based on these fi ndings, an MS biomarker panel of 
30 metabolites was created by modifying a previous MS 
method 20 to include the putative biomarkers and other 
metabolites within related metabolic pathways. Correla-
tions with neutrophil counts and clinical measures were 
then assessed in an independent validation set of BALF 
samples from 25 children with CF. 
 Purine Metabolism:  Th e purine nucleotide adenosine 
monophosphate (AMP) was positively correlated with 
neutrophilic counts, and adenosine exhibited a trend 
toward negative correlation ( Table 3 ), both similar to 
previous observations. 4 Downstream purine metabo-
lites, including inosine, hypoxanthine, and xanthine, 
were strongly and positively correlated with neutro-
philic counts, with hypoxanthine and xanthine exhibit-
ing about three orders of magnitude concentration 
diff erences between the lowest and highest infl amma-
tion samples. 
 Polyamine Metabolism:  Th e polyamines putrescine, 
spermidine, and spermine, as well as S-adenosyl-
methionine and adenine, positively correlated with 
neutrophilic infl ammation ( Table 3 ). Th e spermidine to 
spermine ratio, reportedly reduced in CF exacerbation, 21 
exhibited a trend toward negative correlation with neu-
trophil counts ( r  5  2 0.37,  P  5 .07). Of note, the peak asso-
ciated with adenine eluted at a run time (about 4.2 min) 
substantially diff erent from that of authentic adenine 
standard (about 2.5 min) and could not be confi rmed. 
 Protein Catabolism:  Strong correlations with neutro-
phil counts were observed for multiple amino acids 
( Table 3 ), with MS signals varying by more than three 
orders of magnitude. Strong correlations were observed 
for multiple dipeptides, consistent with formation 
during protein catabolism. 19 As a further control, previ-
ously described methods 22 were used to demonstrate 
that the proline-glycine-proline proteolytic fragment of 
fi bronectin, known to correlate with infl ammation, also 
correlated with neutrophil counts ( r  5 0.84,  P  , .001). 
 Nicotinamide:  Nicotinamide and two related metabo-
lites, nicotinamide adenine diphosphate and nicotin-
amide mononucleotide, were positively, albeit modestly, 
correlated with neutrophil counts. 
 Controlling for Dilution 
 Urea, commonly used as a BALF dilution marker, was 
included in the MS biomarker panel and correlated 
with neutrophil counts ( r  5 0.73,  P  , .001). Because this 
suggested that infl ammation may have impacted the 
dilution of airway secretions in BALF, we performed a 
secondary analysis of each putative biomarker as a ratio 
to urea relative to percent neutrophils as a dilution-
independent infl ammatory marker ( e-Table 2 ). Hypo-
xanthine, xanthine, and most amino acids and dipeptides 
remained correlated with neutrophils as ratios to urea, 
 Figure 1 – MS metabolomics. A, Relationship between neutrophil (PMN) 
count and total MS signal during discovery metabolomics. Signal for 
each peak was normalized such that the lowest signal in the dataset 
had a value of 1. A strong correlation ( r  5 0.70,  P  , .001) was observed 
between neutrophil counts and total MS metabolomics signal. B, Princi-
pal component analysis of metabolomic data. Low infl ammation samples 
(  ) generally clustered together away from high infl ammation samples 
(  ), but with some overlap. MS  5 mass spectrometry; PC  5 principal 
component; PMN  5 polymorphonuclear leukocyte . 
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 TABLE 3  ]  Correlations Between Metabolites Identifi ed by MS Metabolomics and Neutrophils in Validation 
Dataset 
Metabolic Pathway Metabolite No. Detected
Correlation
 r  P Value
Purine metabolism AMP 25 0.47 .019
Adenosine 25  2 0.32 .112
Inosine 25 0.72 a  , .0001 a 
Hypoxanthine 22 0.84 a  , .0001 a 
Xanthine 24 0.84 a  , .0001 a 
Uric acid 24 0.63 a .001 a 
Polyamine metabolism Spermine 25 0.67 a  , .0001 a 
Putrescine 25 0.54 .045
Spermidine 25 0.57 .003
N-Ac-spermidine 25 0.78 a  , .0001 a 
S-adenosyl-methionine 16 0.62 .002
Adenine-like 23 0.64 .002
Protein catabolism Proline 25 0.82 a  , .0001 a 
Valine 22 0.82 a  , .0001 a 
Leucine 25 0.86 a  , .0001 a 
Glutamine 25 0.83 a  , .0001 a 
Phenylalanine 25 0.87 a  , .0001 a 
Tryptophan 25 0.86 a  , .0001 a 
Threonine 25 0.83 a  , .0001 a 
Alanine 21 0.81 a  , .0001 a 
Tyrosine 25 0.87 a  , .0001 a 
Leu-Pro 24 0.87 a  , .0001 a 
Lys-Leu 22 0.79 a  , .0001 a 
Gly-Pro 21 0.75 a  , .0001 a 
Thr-Phe 25 0.69 a .0001 a 
Leu-Phe 23 0.75 a  , .0001 a 
Pro-Gly-Pro 24 0.84 a  , .0001 a 
Nicotinamide metabolism Nicotinamide 25 0.62 a .001 a 
NAD 25 0.46 .021
NMN 23 0.62 .009
 Relationships to neutrophil counts were assessed using Pearson correlations after log transformation.  P values for correlations are shown. 
AMP  5 adenosine monophosphate; Gly-Pro  5 glycine-proline; Leu-Phe  5 leucine-phenylalanine; Leu-Pro  5 leucine-proline; Lys-Leu  5 lysine-leucine; 
MS  5 mass spectrometry; NAD  5 nicotinamide adenine diphosphate; NMN  5 nicotinamide mononucleotide; Pro-Gly-Pro  5 proline-glycine-proline; 
Thr-Phe  5 threonine-phenylalanine . 
 a Signifi cant after Bonferroni multiple-test correction. 
but polyamines and nicotinamide were not. However, 
these results should be interpreted with caution given 
the limitations of urea as a BALF dilution marker, 23 par-
ticularly because urea is generated during polyamine 
synthesis. 21 
 Impact of Infection 
 Neutrophilic infl ammation correlates with the severity 
of infection, 24 suggesting that airway pathogens may 
contribute to the metabolomic signal. In fact, bio-
markers from each pathway were elevated in samples 
with bacterial pathogens (n  5 15) relative to those with 
no pathogens (n  5 5) ( Fig 2 ). However, biomarker con-
centrations did not diff er between samples that cultured 
exclusively gram-positive cocci ( Staphylococcus aureus 
[n  5 7]) vs only gram-negative rods ( Pseudomonas , 
 Burkholderia , or  Stenotrophomonas species [n  5 5]). 
Correlations between biomarker metabolites and bacterial 
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counts (organisms/mL) were observed, although they 
were less robust than correlations with neutrophil counts, 
and most metabolites remained positively correlated 
with neutrophil counts even among samples that did 
not grow bacterial pathogens ( Table 4 ). 
 Relationship to Clinical Markers 
 We observed a signifi cant negative correlation between 
BALF neutrophil counts and percent predicted FEV 1 
in our validation set ( r  5  2 0.58,  P  , .01) ( Fig 3A ), sim-
ilar to previous fi ndings. 3 Many biomarker metabolites, 
including hypoxanthine, xanthine, and several amino 
acids and dipeptides, were also negatively correlated 
with percent predicted FEV 1 ( Fig 3B ). Less robust 
correlations for polyamines and a trend toward correla-
 Figure 2 – Biomarkers and infection. A, Diff erences in BAL fl uid (BALF) 
neutrophil counts were observed among samples with no pathogens on 
culture (white, n  5 5), fungal pathogens only (hatched, n  5 5), or bacte-
rial pathogens (gray, n  5 15). * P  , .05 by analysis of variance (ANOVA), 
Tukey posttest indicating diff erences between no pathogen and bacterial 
pathogen groups. B, Multiple metabolomics biomarkers also diff erenti-
ated among BALF culture status, including some metabolites (**) that 
diff erentiated samples with bacterial pathogens from both no pathogen 
and fungal pathogen-only groups (Tukey posttest following ANOVA). 
Hyp  5 hypoxanthine; Leu  5 leucine; Leu-Pro  5 leucine-proline dipeptide; 
Nic  5 nicotinamide; NSp  5 N-acetyl spermidine; Phe  5 phenylalanine; 
Spm  5 spermine; Xan  5 xanthine. See  Figure 1 legend for expansion of 
other abbreviations. 
 TABLE 4  ]  Correlations Between Representative 
Metabolites and Airway Infection 
Biomarker
Bacterial 
Counts (n  5 15)
PMNs, No Bacteria 
(n  5 10)
 r  P Value  r  P Value
Neutrophil 
counts
0.58  , .05 … …
Hypoxanthine 0.55  , .05 0.76  , .02
Xanthine 0.60  , .02 0.81  , .01
Spermine 0.38 .16 0.41 .24
N-Ac-Spermidine 0.22 .45 0.62 .06
Leucine 0.55  , .05 0.72  , .05
Phenylalanine 0.59  , .05 0.75  , .05
Leu-Pro 0.31 .28 0.83  , .01
Nicotinamide 0.36 .19 0.79  , .01
 See  Table 1 and 3 legends for expansion of abbreviations. 
 Figure 3 – BALF biomarkers and lung function. A, Percent predicted 
FEV 1 was signifi cantly negatively correlated with BALF neutrophil 
(PMN) counts ( r  5  2 0.57,  P  , .01). B, Similar correlations were 
observed for BALF purines (Hyp,  r  5  2 0.56; Xan,  r  5  2 0.56;  P  , .01) 
and protein catabolism metabolites (Leu,  r  5  2 0.61; Phe,  r  5  2 0.59; 
Leu-Pro,  r  5  2 0.59;  P  , .01). C, Correlations with percent predicted 
FEV 1 were observed for polyamines (Spm,  r  5  2 0.44,  P  , .05) with a 
trend for Nic ( r  5  2 0.36,  P  , .11). D, Ado, but no other metabolite, 
was negatively correlated with changes in predicted FEV 1 over time 
( r  5  2 0.71,  P  , .001 ). Ado  5 adenosine . See  Figure 1 and 2 legends for 
expansion of other abbreviations. 
tion for nicotinamide were also observed ( Fig 3C ). 
Biomarker metabolite concentrations were not predic-
tive of changes in FEV 1 following sample collection 
(average 3.0   0.7 years of data), with the exception 
of adenosine, which demonstrated a signifi cant nega-
tive correlation ( Fig 3D ). No metabolites were signifi-
cantly correlated with BMI percentile as a nutritional 
marker. 
 Biomarker Panel in COPD 
 Representative biomarker metabolites were elevated in 
subjects with COPD relative to healthy nonsmokers, 
and a subset diff erentiated those with COPD from 
healthy smokers ( Fig 4A ). All metabolites were sig-
nifi cantly correlated with BALF neutrophil counts 
( r  5 0.42-0.62,  P  , .05 for all), and negative correlations 
with percent predicted FEV 1 were observed for hypo-
xanthine ( r  5  2 0.57), xanthine ( r  5  2 0.39), leucine 
( r  5  2 0.44), phenylalanine ( r  5  2 0.48), and nicotin-
amide ( r  5  2 0.50) ( Fig 4B ), with a trend for spermine 
( r  5  2 0.32,  P  5 .053). 
 Discussion 
 Our data demonstrate that the infl amed CF airway is a 
metabolically rich environment. Although the airway 
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 Figure 4 – Biomarker metabolites in COPD. A, Biomarker metabolites 
were measured in BALF from healthy nonsmokers (n  5 10, white bars), 
healthy smokers (n  5 10, hatched bars), and patients with COPD 
(n  5 10, gray bars). Biomarker metabolites diff erentiated COPD sam-
ples from those of healthy nonsmokers (*) or from both healthy non-
smokers and healthy smokers (**); ANOVA with Tukey posttest. 
B, Biomarkers Hyp ( r  5  2 0.57,  P  , .001), Leu ( r  5  2 0.44,  P  , .01), 
and Nic ( r  5  2 0.50,  P  , .01) and others (not shown) were signifi cantly 
correlated with percent predicted FEV 1 . See  Figure 1 and 2 legends for 
expansion of abbreviations. 
metabolome refl ects a complex interaction among 
airway epithelia, inflammatory cells, and microbial 
pathogens, our data suggest that the metabolites iden-
tified in this study primarily reflect neutrophilic 
inflammation. Correlations were strongest with neutro-
phil counts, and the purine metabolites hypoxanthine 
and xanthine, as well as several amino acids, appeared 
functionally equivalent to neutrophil counts as bio-
markers. Measures of these metabolites using simple, 
commercially available assays could serve as an alterna-
tive means of assessing neutrophilic infl ammation 
when standard cell counts are not available, although 
further investigation is needed to demonstrate the 
validity and reliability relative to established measures. 
Th ese biomarkers may be broadly applicable, because 
they functioned similarly in subjects with CF and 
COPD. 
 Our metabolomics studies also identifi ed novel pathways 
involved in disease pathogenesis. For example, we dem-
onstrated that several adenosine metabolites strongly 
correlated with airway neutrophils, suggesting that the 
infl amed CF airway exhibits a robust extracellular 
metabolism of adenosine that may play a signifi cant role 
in modulating purinergic signaling responses to infl am-
mation. 25 Accumulation of hypoxanthine in infl amed 
CF airways is consistent with fi ndings from asthma, 26 
bronchopulmonary dysplasia, 27 and ARDS, 28 and may 
contribute to oxidative stress, because its metabolism to 
xanthine and uric acid generates oxygen superoxides. 27,28 
Th us, existing pharmacologic agents that block hypoxan-
thine formation 29 may be considered as therapeutic can-
didates in CF and other airways diseases. 
 Th e correlations of airway neutrophils with amino acids 
and dipeptides are consistent with the known roles of 
extracellular airway proteases, including those derived 
from neutrophils, in CF airways disease. 30 Although 
elevated amino acid concentrations in CF airway secretions 
has been described previously, 5,31,32 the strong relation-
ships between the markers of protein catabolism and 
the inflammatory, infection, and clinical measures 
observed here suggest that these metabolites could serve 
as biomarkers of in vivo protease activity in trials of 
protease inhibitors. 
 Elevated polyamine concentrations have been reported 
in CF sputum 21 and may increase mucin secretion 33 and 
aggregation. 34 Interestingly, genetic studies suggest that 
activity of the methionine salvage pathway, which plays 
a critical role in polyamine synthesis, is increased in 
patients with CF who have more severe lung disease. 35 
Th ese fi ndings suggest that polyamines may be both a 
biomarker and a therapeutic target for CF airways 
disease and COPD. 
 Nicotinamide is known to have antiinfl ammatory prop-
erties, but an association between nicotinamide and 
airways disease has not been described previously. Free 
nicotinamide can be generated by extracellular ADP-
ribosyl-transferases 36 that modulate crosstalk between 
epithelia and neutrophils in infl amed airways. 37 Th is 
pathway may be responsible for our fi ndings, although 
further study is needed. 
 Th e metabolites identifi ed in this study could also be 
used as noninvasive biomarkers of airways disease. MS 
methods similar to those used in this study have been 
used to assess EBC as a noninvasive airway sample. 14,20,38 
However, although biomarkers such as AMP function 
similarly in BALF and EBC, 4,38 the relationships 
between infl ammation and adenosine and phenylala-
nine in the current study diff er from previous observa-
tions in EBC. 14,20,38 Th us, EBC and BALF may diff er in 
the metabolites that function optimally as biomarkers, 
perhaps refl ecting diff erent sites of origin of the airway 
secretions, 39,40 and further study will be needed to iden-
tify the most eff ective metabolomic biomarkers for non-
invasive detection. 
 Although we took steps to minimize enzymatic activity 
aft er sample collection, we cannot rule out the possi-
bility that extracellular metabolism during sample col-
lection or processing infl uenced our results. Similarly, 
although subjects were fasting at the time of sample 
collection, it is possible that dietary variations altered 
metabolite concentrations. However, given the strength 
of our fi ndings, we do not believe that either of these 
potential confounders would signifi cantly alter out 
conclusions. 
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